We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Autoimmune Disease Discovered Causes Kidney Failure

By LabMedica International staff writers
Posted on 15 Nov 2017
Print article
Image: A photomicrograph of a renal biopsy specimen suggesting acute tubular necrosis is the patchy or diffuse denudation of the renal tubular cells with loss of brush border (blue arrow) (Photo courtesy of the University of Alberta).
Image: A photomicrograph of a renal biopsy specimen suggesting acute tubular necrosis is the patchy or diffuse denudation of the renal tubular cells with loss of brush border (blue arrow) (Photo courtesy of the University of Alberta).
An insidious new autoimmune disease that causes kidney failure has been discovered. The condition causes a build-up of waste products in the blood and makes it difficult for kidneys to maintain adequate balance of fluid in the body.

Scientists have discovered for the first time that in the nephrons, the functional units of the kidneys, had coated a specialized part of cells called brush borders, which help reabsorb and process proteins.

A team of scientists collaborating with those at the University of Louisville (Louisville, KY, USA) identified anti-brush border antibody (ABBA) after analyzing biopsied kidney tissue from 10 patients. Those who were identified had a combination of proximal tubule damage, immunoglobulin G (IgG)-positive immune deposits in the tubular basement membrane, and circulating antibodies reactive with normal human kidney proximal tubular brush border. Immunoblotting of a protein extract from human tubular cells was performed with serum from cases and controls, and immunoprecipitation followed by mass spectrometry was used to identify the protein targeted by the anti-brush border antibodies. Cell expression of recombinant protein followed by immunoblotting and immunoprecipitation was used to confirm the identity of the antigen.

The patients with ABBA disease were elderly (mean age 72.9 years), presented with acute kidney injury (median serum creatinine 4.0 mg/dL) and moderate proteinuria. The kidney biopsy showed acute tubular injury with apical cytoplasmic blebbing, loss of brush border, regenerative changes and granular IgG and C3 deposits along tubular basement membranes. All patient sera were reactive to the proximal tubular brush border on sections of normal human kidney. Serum from all patients but not controls recognized a high molecular weight protein in renal tubular protein extracts that was identified as low-density lipoprotein receptor-related 2 (LRP2) by immunoprecipitation and mass spectrometry. Recombinant expression of an N-terminal recombinant fragment of LRP2 was used to confirm this finding by Western blot and immunoprecipitation. LRP2 specifically co-localized with IgG in the tubular immune deposits.

Jon B. Klein, MD, PhD, a professor of medicine and director of the Core Proteomics Laboratory, said, “It's the first time in my career that I've described a new disease, and truthfully, most people in their career don't stumble on this. We don't know yet whether this causes kidney failure in a lot of people. It's early in the story. The disease is rather insidious. It was documented in a group of older men who simply turned up with abnormal kidney function, and there were no symptoms until they had very advanced kidney failure.” The study was presented on November 3, 2017, at the American Society of Nephrology's Annual Meeting held in New Orleans, LA, USA.

Related Links:
University of Louisville

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multichannel Pipette
CAPPSolo
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.